🕒 Last update: loading…21/11/2026

Stock Evelo Biosciences, Inc. EVLO

Evelo Biosciences, Inc. — Investlytic score 0/5 on the five criteria.

-
-
0/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 0/5 criteria met. Data as of 01/11/2026.

  • ❌ Price trend failed
  • ❌ Growth failed
  • ❌ Debt failed
  • ❌ P/E failed
  • ❌ Correction failed

Price trend

Overall trend (8 years): insufficient progression (less than x1.5).

Price change 2018 → 2019: -68.79%

Price change 2019 → 2020: 197.78%

Price change 2020 → 2021: -49.79%

Price change 2021 → 2022: -73.48%

Price change 2022 → 2023: -99.81%

Price change 2023 → 2024: -99.19%

Price change 2024 → 2025: -0.00%

Price change 2025 → 2026: -80.00%

Price change 2026 (year to date): -80.00%

Financial growth

Revenue CAGR (7 years): N/A

Earnings CAGR (7 years): N/A

Growth status: insufficient data or negative trend.

Debt

Negative or zero equity.

P/E (Price/Earnings)

P/E ratio not available.

Correction (6 months)

Current correction: 66.67% from the high over 6 months.

Excessive correction (> 20.0%).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, model verdict (buy, watch, sell) and details of the 5 criteria · visible with a free account.

02

Price trend

Price & trend

Interactive chart →
Loading chart…
03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

+

Accounts and financial health

Balance sheet and cash flow published by Evelo Biosciences, Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).

Overview
fragile accounts
according to Altman Z, Piotroski and net debt
Altman Z-score
-53.28
risk zone (below 1.81)
Piotroski Score
3 / 9
0 to 3: fragile accounts
Net Debt / EBITDA
-0.03 x
net cash
Fiscal year202020212022
Share buybacks000
Dividends paid000

Amounts in USD, currency of the published accounts.

Trailing 12-month ratios

Return on Equity (ROE)-6,232.8 %
Return on Invested Capital (ROIC)-199.7 %
Net margin0.0 %
Debt / equity-10.24 x
Current ratio4.16 x
Interest coverage-23.22 x

Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 20/11/2026.

+

Valuation and competitors

Evelo Biosciences, Inc. compared with its sector on the same exchange and with its main competitors.

Direct competitors

CompanyMarket cap (USD)P/ENet margin
Evelo Biosciences, Inc.1,898n/an/a
Infinity Pharmaceuticals, Inc. INFIQ9,076n/an/a
Life Stem Genetics Inc. LIFS24,584n/a0.0 %
Aridis Pharmaceuticals, Inc. ARDS4,457n/an/a
Statera Biopharma, Inc. STAB14,283n/an/a
Trevena, Inc. TRVN9,588n/an/a
HST Global, Inc. HSTC209 mn/a-164.3 %
PaxMedica, Inc. Common Stock PXMD88,385n/an/a
Biostax Corp. BTAX15,743n/an/a

Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 13/11/2026. Competitors: comparable companies named by the data provider.

+

Dividends and earnings

Evelo Biosciences, Inc.: dividend history, last distributions, stock splits and earnings releases.

No known dividend for this company.

Stock splits

DateOperation
30/06/2023reverse split: 1 share for 20

Factual data: ex-dividend history and earnings calendar, as of 20/11/2026. A past dividend does not guarantee the next one.

+

Who owns the stock

Free float, institutional investors, large funds, executives and elected officials: declared positions in Evelo Biosciences, Inc.

Free float
99.5 %
share of freely traded shares

Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 07/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.

+

PEA and practical information

PEA eligibility
no
head office outside the EU and EEA
Listing exchange
OTC (hors cote)
IPO: 08/05/2018
ISIN code
US2997342025
Workforce
66
full-time employees
Chief executive
Craig R. Jalbert CIRA

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about Evelo Biosciences, Inc.

What is the Evelo Biosciences, Inc. share price?

Latest recorded price: 0.0001 USD on 13/11/2026, for a market cap of 1,898 USD.

Is Evelo Biosciences, Inc. stock eligible for the French PEA?

No: the company is headquartered outside the European Union and the European Economic Area (ISIN US2997342025).

How many employees does Evelo Biosciences, Inc. have?

66 full-time employees according to the latest published profile.

Who runs Evelo Biosciences, Inc.?

Craig R. Jalbert CIRA is the company's chief executive.